Comparison of Risperidone and Mosapramine Addition to Neuroleptic Treatment in Chronic Schizophrenia

  title={Comparison of Risperidone and Mosapramine Addition to Neuroleptic Treatment in Chronic Schizophrenia},
  author={Norito Takahashi and Takeshi Terao and Tetsuo Oga and Masakatsu Okada},
  pages={81 - 85}
There is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia. As a preliminary study, 10 neuroleptic-treated schizophrenic inpatients received risperidone (high 5HT2A/D2 ratio, i.e. the ratio between 5HT2A and D2 receptor occupancy) and mosapramine (low 5HT2A/D2 ratio) in a randomized, single-blind, crossover, add-on study consisting of 8 weeks of treatment each with risperidone and mosapramine. Although both additions resulted in… 

Tables from this paper

Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
This review includes 71 studies comparing chlorpromazine to olanzapine, risperidone or quetiapine for treating people with schizophrenia, and finds no difference between drugs for relapse, quality of life ratings or any observed extrapyramidal symptoms.
Atypical antipsychotic agents were developed in response to problems with typical agents, including lack of efficacy in some patient s, lack of improvement in negative symptoms, and troublesome adverse effects, especially extrapyramidal symptoms (EPSs) and tardive dyskinesia (TD).
Treatment-refractory schizophrenia: what is it and what has been done about it?
There has been a veritable explosion of research conducted for interventions that may be advantageous for the management of treatment-refractory schizophrenia, and research being done with antidepressant medications and with agents that impact on the glutamate receptor holds the greatest promise at this time.
Benefits and Risks of Antipsychotic Polypharmacy
From an evidence-based perspective, further trials of antipsychotics association of sufficient power to address safety issues are needed before recommending any antipsychotic combination, and particular weaknesses of the present literature are low number of participants, lack of adequate control of confounding variables, short duration of experimental follow-up and inadequate monitoring of potential adverse effects.
A systematic review of atypical antipsychotic drugs in schizophrenia.
The main objectives were to assess the clinical effectiveness, safety and cost-effectiveness of 'atypical' antipsychotic drugs in schizophrenia in comparison with conventional anti-schizophrenia drugs, placebo and other atypical antipsychotics.
An electrolyte- and catalyst-free electrooxidative sulfonylation of imidazo[1,2-a]pyridines
An electrolyte- and catalyst-free electrooxidative C–H activation reaction is developed to afford 3-sulfonylated imidazo[1,2-a]pyridines in good to excellent yields.


Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
In an open 4-week trial involving 12 treatment-resistant schizophrenic patients, the addition of risperidone to clozapine was well tolerated and produced significant reduction of symptoms, suggesting that this may be a useful clinical approach.
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study
R risperidone is comparable to haloperidol as an antipsychotic, but that it has a safer EPS profile, according to the laboratory, endocrinological and cardiovascular safety parameters.
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Risperidone was well tolerated and as effective as medium doses of clozapine in patients with chronic schizophrenia who had been resistant to or intolerant of conventional neuroleptics.
Observations on switching patients with schizophrenia to risperidone treatment
The strategy appeared to be successful for most patients, especially those who had previously received depot medication, however, more gradual withdrawal of previous treatments, including anticholinergics, may be advisable in some cases.
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Patients with OCD and related disorders are not infrequently refractory to treatment with serotonin reuptake inhibitors and controlled trials of risperidone augmentation in such patients seem warranted, it is necessary to determine an appropriate dose range to minimize adverse effects.
Risperidone: clinical safety and efficacy in schizophrenia.
It is suggested that risperidone may offer a superior side-effect profile, and possibly greater efficacy, than a standard neuroleptic such as haloperidol.
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
It is suggested that risperidone, at the optimal therapeutic dose of 6 mg/day, produced significant improvement in both positive and negative symptoms without an increase in drug-induced parkinsonian symptoms and with a significant beneficial effect on tardive dyskinesia.
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
It is suggested that risperidone augmentation is effective and well tolerated in patients with SRI-refractory obsessive-compulsive disorder and controlled trials are required to confirm the efficacy.
Long‐term treatment of chronic schizophrenia with risperidone: an open‐label? multicenter study of 386 patients
It is demonstrated that risperidone's efficacy against the positive and negative symptoms of chronic schizophrenia can be maintained in long-term treatment with a low incidence of adverse experiences; moreover, the drug reduces preexisting extrapyramidal symptoms Over time.
The use of risperidone in treatment-resistant schizophrenia: two case reports.
Two patients with treatment-resistant schizophrenia characterized by unremitting delusions, thought disorder and self-neglect who had a sustained improvement in their symptoms soon after starting risperidone are described.